Literature DB >> 13201852

The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria.

J ARNOLD, A S ALVING, R S HOCKWALD, C B CLAYMAN, R J DERN, E BEUTLER, G M JEFFERY.   

Abstract

Entities:  

Keywords:  ANTIMALARIALS/therapeutic use; MALARIA/therapy

Mesh：

Substances：

Year:  1954        PMID： 13201852

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


× No keyword cloud information.
  9 in total

1.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 2.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

3.  Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report.

Authors:  A S ALVING; C F JOHNSON; A R TARLOV; G J BREWER; R W KELLERMEYER; P E CARSON
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

Review 5.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Failure of Supervised Chloroquine and Primaquine Regimen for the Treatment of Plasmodium vivax in the Peruvian Amazon.

Authors:  Paul C F Graf; Salomon Durand; Carlos Alvarez Antonio; Carmen Montalvan; Mariella Galves Montoya; Michael D Green; Meddly L Santolalla; Carola Salas; Carmen Lucas; David J Bacon; David J Fryauff
Journal:  Malar Res Treat       Date:  2012-05-31

Review 7.  Management of relapsing Plasmodium vivax malaria.

Authors:  Cindy S Chu; Nicholas J White
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-31       Impact factor: 5.091

8.  Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.

Authors:  Erin E Milner; Jonathan Berman; Diana Caridha; Samuel P Dickson; Mark Hickman; Patricia J Lee; Sean R Marcsisin; Lisa T Read; Norma Roncal; Brian A Vesely; Lisa H Xie; Jing Zhang; Ping Zhang; Qigui Li
Journal:  Malar J       Date:  2016-12-07       Impact factor: 2.979

Review 9.  The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).

Authors:  Geoffrey Dow; Bryan Smith
Journal:  Malar J       Date:  2017-05-19       Impact factor: 2.979
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.